Dashyant Dhanak - Feb 15, 2024 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role
EVP & Chief Scientific Officer
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Stock symbol
DCPH
Transactions as of
Feb 15, 2024
Transactions value $
$0
Form type
4
Date filed
2/20/2024, 04:05 PM
Previous filing
Sep 19, 2023
Next filing
Jun 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DCPH Common Stock Award $0 +17.3K +12.26% $0.00 158K Feb 15, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DCPH Stock Option (Right to Buy) Award $0 +69.1K $0.00 69.1K Feb 15, 2024 Common Stock 69.1K $15.92 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person was awarded 17,275 Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs shall vest in three equal installments on each of February 15, 2025, February 15, 2026 and February 15, 2027.
F2 This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2024.